Baxalta US Inc. [clinicaltrials_resource:5716b9aa6b652d93955eca87736328fd]
Brahm Goldstein, MD [clinicaltrials_resource:2fa2c6da60523bdf70c0c02cffe39d9d]Xiaochun Liu, MD, PhD [clinicaltrials_resource:669b07489d428e55528771d63e892c3a]Brahm Goldstein, MD [clinicaltrials_resource:a360c53edb31046ea73d64b36c969e43]Xiaochun Liu, MD, PhD [clinicaltrials_resource:c588e86105f6d510588154a5780cd8f6]
affiliation [clinicaltrials_vocabulary:affiliation]
Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency [clinicaltrials:NCT00157092]Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency [clinicaltrials:NCT00161707]ADVATE Post Authorization Safety Surveillance [clinicaltrials:NCT00214734]clinicaltrials:NCT00242385Pharmacokinetic (PK) and Safety Study of Plasma-derived Human Butyrylcholinesterase Administered Intravenously [clinicaltrials:NCT00333515]A Study of Plasma-Derived Human Butyrylcholinesterase Administered Intramuscularly [clinicaltrials:NCT00333528]clinicaltrials:NCT00818662BAX 326 (rFIX) Continuation Study [clinicaltrials:NCT01286779]clinicaltrials:NCT01376700Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD) [clinicaltrials:NCT01410227]Phase 1/2 Lyme Vaccine Study [clinicaltrials:NCT01504347]BAX 326 Surgery Study in Hemophilia B Patients [clinicaltrials:NCT01507896]clinicaltrials:NCT01597401BAX 855 Dose-Escalation Safety Study [clinicaltrials:NCT01599819]Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures [clinicaltrials:NCT01913405]ADVATE Hemophilia A Outcome Database (AHEAD) [clinicaltrials:NCT02078427]China ADVATE PTP Study [clinicaltrials:NCT02170402]BAX 855 Pediatric Study [clinicaltrials:NCT02210091]Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery [clinicaltrials:NCT02283268]
collaborator [clinicaltrials_vocabulary:collaborator]
Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation [clinicaltrials:NCT00003056]Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A [clinicaltrials:NCT00157040]Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901 [clinicaltrials:NCT00157053]Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders [clinicaltrials:NCT00157079]Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency [clinicaltrials:NCT00157092]Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery [clinicaltrials:NCT00157105]Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency [clinicaltrials:NCT00157118]clinicaltrials:NCT00157157Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency [clinicaltrials:NCT00161707]Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND [clinicaltrials:NCT00161720]Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia) [clinicaltrials:NCT00161993]Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura [clinicaltrials:NCT00162006]Pharmacokinetics, Efficacy and Safety Study of IMMUNATE SD (Human Plasma-Derived Coagulation Factor VIII Concentrate) in Hemophilia A Patients [clinicaltrials:NCT00162019]Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101 [clinicaltrials:NCT00189982]ADVATE Post Authorization Safety Surveillance [clinicaltrials:NCT00214734]clinicaltrials:NCT00242385clinicaltrials:NCT00243386clinicaltrials:NCT00289536clinicaltrials:NCT00313144Pharmacokinetic (PK) and Safety Study of Plasma-derived Human Butyrylcholinesterase Administered Intravenously [clinicaltrials:NCT00333515]A Study of Plasma-Derived Human Butyrylcholinesterase Administered Intramuscularly [clinicaltrials:NCT00333528]Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery [clinicaltrials:NCT00357656]clinicaltrials:NCT00396006ACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study) [clinicaltrials:NCT00545610]clinicaltrials:NCT00546871clinicaltrials:NCT00666263clinicaltrials:NCT00666406Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease [clinicaltrials:NCT00816660]clinicaltrials:NCT00818662clinicaltrials:NCT00851721clinicaltrials:NCT00916032clinicaltrials:NCT00952822Phase 1 Dosing Study of BAX 513 in Healthy Volunteers [clinicaltrials:NCT01063101]Ceprotin Treatment Registry [clinicaltrials:NCT01127529]IMMUNINE Pre-Treatment Study [clinicaltrials:NCT01128881]Efficacy and Safety of Prothromplex Total (Prothrombin Complex Concentrate) in Oral Anticoagulant Reversal [clinicaltrials:NCT01159210]clinicaltrials:NCT01174446First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients [clinicaltrials:NCT01191372]Phase 2/3 Study of IGSC, 20% in PIDD [clinicaltrials:NCT01218438]BAX 326 (rFIX) Continuation Study [clinicaltrials:NCT01286779]
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation [clinicaltrials:NCT00003056]Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A [clinicaltrials:NCT00157040]Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901 [clinicaltrials:NCT00157053]Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders [clinicaltrials:NCT00157079]Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency [clinicaltrials:NCT00157092]Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery [clinicaltrials:NCT00157105]Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency [clinicaltrials:NCT00157118]clinicaltrials:NCT00157157Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency [clinicaltrials:NCT00161707]Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND [clinicaltrials:NCT00161720]Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia) [clinicaltrials:NCT00161993]Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura [clinicaltrials:NCT00162006]Pharmacokinetics, Efficacy and Safety Study of IMMUNATE SD (Human Plasma-Derived Coagulation Factor VIII Concentrate) in Hemophilia A Patients [clinicaltrials:NCT00162019]Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101 [clinicaltrials:NCT00189982]ADVATE Post Authorization Safety Surveillance [clinicaltrials:NCT00214734]clinicaltrials:NCT00242385clinicaltrials:NCT00243386clinicaltrials:NCT00289536clinicaltrials:NCT00313144Pharmacokinetic (PK) and Safety Study of Plasma-derived Human Butyrylcholinesterase Administered Intravenously [clinicaltrials:NCT00333515]A Study of Plasma-Derived Human Butyrylcholinesterase Administered Intramuscularly [clinicaltrials:NCT00333528]Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery [clinicaltrials:NCT00357656]clinicaltrials:NCT00396006ACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study) [clinicaltrials:NCT00545610]clinicaltrials:NCT00546871clinicaltrials:NCT00666263clinicaltrials:NCT00666406Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease [clinicaltrials:NCT00816660]clinicaltrials:NCT00818662clinicaltrials:NCT00851721clinicaltrials:NCT00916032clinicaltrials:NCT00952822Phase 1 Dosing Study of BAX 513 in Healthy Volunteers [clinicaltrials:NCT01063101]Ceprotin Treatment Registry [clinicaltrials:NCT01127529]IMMUNINE Pre-Treatment Study [clinicaltrials:NCT01128881]Efficacy and Safety of Prothromplex Total (Prothrombin Complex Concentrate) in Oral Anticoagulant Reversal [clinicaltrials:NCT01159210]clinicaltrials:NCT01174446First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients [clinicaltrials:NCT01191372]Phase 2/3 Study of IGSC, 20% in PIDD [clinicaltrials:NCT01218438]BAX 326 (rFIX) Continuation Study [clinicaltrials:NCT01286779]
source [clinicaltrials_vocabulary:source]
Baxalta US Inc. [clinicaltrials_resource:5716b9aa6b652d93955eca87736328fd]
Bio2RDF identifier
5716b9aa6b652d93955eca87736328fd
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:5716b9aa6b652d93955eca87736328fd
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:5716b9aa6b652d93955eca87736328fd
title
Baxalta US Inc.
@en
type
label
Baxalta US Inc. [clinicaltrials_resource:5716b9aa6b652d93955eca87736328fd]
@en